Last reviewed · How we verify
NCT07020156
A First-in-Human Phase I Trial of OX118 in Healthy Volunteers
Phase 1 trial testing OX118 or placebo in Immune System in 32 participants. Currently enrolling.
29 October 2025
Quick facts
| Lead sponsor | Oxion Biologics AB |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 3 April 2025 |
| Primary completion | 29 October 2025 |
| Estimated completion | 29 October 2025 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- OX118 or placebo — full drug profile →
Conditions studied
- Immune System — all drugs for Immune System →
Sponsor
Oxion Biologics AB — full company profile →
Who can join
Adults 18 to 60, any sex, with Immune System. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a first-in-human, phase 1 study of OX118 in healthy volunteers, designed to investigate the safety and tolerability of OX118, as well as its pharmacokinetics (the drug's concentration in the blood and excretion from the body). The study will include a total of 32 participants: healthy men and women aged 18-60 years with a body mass index (BMI) between ≥18.5 and ≤30.0.The study is divided into five cohorts where OX118 will be given as a single dose intravenously (into the blood). The study consists of 7 clinic visits taking place over a period of approximately 77 days (including a 28-day screening period). During the study, subjects will be given the study drug (OX118) or placebo. Both the study drug and the placebo will be given as a single dose as an intravenous (directly into the blood) infusion. A pre-arranged schedule will determine whether subjects will receive the study drug or the placebo.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Tolerance Induction Strategies in Organ Transplantation: Current Status and Future Perspectives.
Blein T, Ayas N, Charbonnier S, Gil A, et al · · 2025 · cited 2× · PMID 41127478 · DOI 10.3389/ti.2025.14958
Verify or expand the search:
- PubMed search for NCT07020156
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Immune System
Currently open trials in the same condition.
- NCT06470607 — The Lymphocytic Infiltrate of Lung Tumors. · recruiting
- NCT05334888 — Sex-differential Host-microbiome CVD Risk - A Longitudinal Cohort Approach · recruiting
- NCT06683248 — The Effects of Night Shift Work on Health Across the Menstrual Cycle · NA · recruiting
- NCT05026242 — Effects of Almond Consumption on Innate and Adaptive Immune System · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07020156 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oxion Biologics AB
- Last refreshed: 13 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07020156.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing